NPS, Kirin deal

NPSP and Kirin's pharmaceutical division (Tokyo) will develop NPSP's Norcalcin and other compounds to treat hyperparathyroidism (HPT) in Japan, China, Korea and Taiwan.

The Salt Lake City company will receive $12 million in non-contingent funding, including a $5 million licensing payment; $2 million in first year research payments; and $5 million in research payments over the next four years of the agreement. NPSP can achieve an additional $13 million in milestones. Kirin receives exclusive rights to develop and sell Norcalcin and certain other compounds in the territories. ...